Melanoma mortality has decreased significantly since the US Food and Drug Administration (FDA) approved ipilimumab in 2011, the first immune checkpoint inhibitor (ICI) to improve survival in the advanced setting [7,8], and vemurafenib, a v-raf murine sarcoma viral oncogene homolog B1 (BRAF) tyrosine kinase inhibitor, first in class [9,10]. This evidence concerns the gene BRAF and melanoma.